Back to today’s briefing

Story perspectives

Harbor Capital Boosts Ardelyx Stake Amid Revenue Challenges

9/26/2025

30 4

Summary

Story summary

Harbor Capital Advisors boosted its Ardelyx, Inc. stake by 79.6% in Q2 2025, lifting institutional ownership to about 59%.
Ardelyx posted $97.66 million in revenue but a negative EPS of $0.08.
The firm focuses on gastrointestinal and cardiorenal diseases, with FDA-approved IBSRELA and XPHOZAH.
It built a robust commercial infrastructure, but execution, reimbursement, and profitability remain challenges.

1 of 1

Story summary

Harbor Capital Advisors boosted its Ardelyx, Inc. stake by 79.6% in Q2 2025, lifting institutional ownership to about 59%.
Ardelyx posted $97.66 million in revenue but a negative EPS of $0.08.
The firm focuses on gastrointestinal and cardiorenal diseases, with FDA-approved IBSRELA and XPHOZAH.
It built a robust commercial infrastructure, but execution, reimbursement, and profitability remain challenges.